Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
(2002) In Blood 100(12). p.3925-3929- Abstract
- Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of... (More)
- Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of prognosis. After 80 months of follow-up, myeloma patients with low levels (< 13 nM) of serum IGF-1 had not reached median survival. In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/322877
- author
- Standal, T ; Borset, M ; Lenhoff, S ; Wisloff, F ; Stordal, B ; Sundan, A ; Waage, A ; Seidel, C ; Turesson, Ingemar LU and Westin, Jan LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 100
- issue
- 12
- pages
- 3925 - 3929
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000179453700010
- pmid:12393395
- scopus:0036892647
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2002-05-1406
- language
- English
- LU publication?
- yes
- id
- 8cc6a8cd-c937-4cb9-9872-76cd085481a6 (old id 322877)
- date added to LUP
- 2016-04-01 11:45:35
- date last changed
- 2024-10-08 08:51:55
@article{8cc6a8cd-c937-4cb9-9872-76cd085481a6, abstract = {{Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of prognosis. After 80 months of follow-up, myeloma patients with low levels (< 13 nM) of serum IGF-1 had not reached median survival. In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression.}}, author = {{Standal, T and Borset, M and Lenhoff, S and Wisloff, F and Stordal, B and Sundan, A and Waage, A and Seidel, C and Turesson, Ingemar and Westin, Jan}}, issn = {{1528-0020}}, language = {{eng}}, number = {{12}}, pages = {{3925--3929}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor}}, url = {{http://dx.doi.org/10.1182/blood-2002-05-1406}}, doi = {{10.1182/blood-2002-05-1406}}, volume = {{100}}, year = {{2002}}, }